AR114001A1 - Anticuerpos que se unen a hla- a2 / wt1 - Google Patents
Anticuerpos que se unen a hla- a2 / wt1Info
- Publication number
- AR114001A1 AR114001A1 ARP180103765A ARP180103765A AR114001A1 AR 114001 A1 AR114001 A1 AR 114001A1 AR P180103765 A ARP180103765 A AR P180103765A AR P180103765 A ARP180103765 A AR P180103765A AR 114001 A1 AR114001 A1 AR 114001A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- hla
- join
- methods
- polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere en general a anticuerpos que se unen a HLA-A2 / WT1, incluidas las moléculas de unión a antígeno biespecíficas, p. ej., para la activación de células T. Además, la presente se refiere a polinucleótidos que codifican tales anticuerpos y vectores y células hospedadoras que comprenden tales polinucleótidos. La presente se refiere además a métodos para producir los anticuerpos y a métodos para usarlos en el tratamiento de enfermedades.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17209205 | 2017-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114001A1 true AR114001A1 (es) | 2020-07-08 |
Family
ID=60702450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103765A AR114001A1 (es) | 2017-12-21 | 2018-12-20 | Anticuerpos que se unen a hla- a2 / wt1 |
Country Status (19)
Country | Link |
---|---|
US (2) | US11192957B2 (es) |
EP (1) | EP3728317A2 (es) |
JP (2) | JP6933778B2 (es) |
KR (1) | KR102575787B1 (es) |
CN (1) | CN111527107A (es) |
AR (1) | AR114001A1 (es) |
AU (1) | AU2018390881A1 (es) |
BR (1) | BR112020011469A2 (es) |
CA (1) | CA3084105A1 (es) |
CL (1) | CL2020001629A1 (es) |
CO (1) | CO2020006600A2 (es) |
IL (1) | IL275471A (es) |
MA (1) | MA51302A (es) |
MX (1) | MX2020006119A (es) |
PE (1) | PE20201149A1 (es) |
PH (1) | PH12020550952A1 (es) |
SG (1) | SG11202005632SA (es) |
TW (1) | TWI805665B (es) |
WO (1) | WO2019122052A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220093323A (ko) | 2019-11-05 | 2022-07-05 | 에프. 호프만-라 로슈 아게 | HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료 |
EP4216998A1 (en) * | 2020-09-24 | 2023-08-02 | F. Hoffmann-La Roche AG | Prevention or mitigation of t-cell bispecific antibody-related adverse effects |
CN118201962A (zh) | 2021-11-01 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 使用HLA-A2/WT1xCD3双特异性抗体和4-1BB(CD137)激动剂治疗癌症 |
CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
WO2024100170A1 (en) | 2022-11-11 | 2024-05-16 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a*02/foxp3 |
WO2024149821A1 (en) | 2023-01-13 | 2024-07-18 | F. Hoffmann-La Roche Ag | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
WO2003102157A2 (en) | 2002-06-03 | 2003-12-11 | Genentech, Inc. | Synthetic antibody phage libraries |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
ES2542885T3 (es) | 2003-01-22 | 2015-08-12 | Roche Glycart Ag | Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
EP1871805B1 (en) | 2005-02-07 | 2019-09-25 | Roche Glycart AG | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof |
KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
CA2625440C (en) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
SI2155783T1 (sl) | 2007-04-03 | 2013-10-30 | Amgen Research (Munich) Gmbh | Medvrstno specifiäśna cd3-epsilon vezavna domena |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
PL2417156T3 (pl) | 2009-04-07 | 2015-07-31 | Roche Glycart Ag | Trójwartościowe, bispecyficzne przeciwciała |
EP3505636A1 (en) | 2009-04-27 | 2019-07-03 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
AU2010252284A1 (en) | 2009-05-27 | 2011-11-17 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
RU2573915C2 (ru) | 2009-09-16 | 2016-01-27 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применение |
LT2519543T (lt) | 2009-12-29 | 2016-10-10 | Emergent Product Development Seattle, Llc | Heterodimerus rišantys baltymai ir jų panaudojimas |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
EP2579897A1 (en) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
SG10201602159VA (en) * | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
SG193956A1 (en) | 2011-04-01 | 2013-11-29 | Sloan Kettering Inst Cancer | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
HUE038225T2 (hu) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák |
MX349095B (es) | 2011-08-23 | 2017-07-11 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno. |
KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
SI2794905T1 (sl) | 2011-12-20 | 2020-08-31 | Medimmune, Llc | Modificirani polipeptidi za ogrodja bispecifičnega protitelesa |
CA2860600C (en) | 2012-02-15 | 2022-07-26 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
JP6553069B2 (ja) * | 2013-11-07 | 2019-07-31 | メモリアル スローン ケタリング キャンサー センター | 抗wt1/hla二重特異性抗体 |
CA2934033A1 (en) | 2013-11-07 | 2015-05-14 | Memorial Sloan-Kettering Cancer Center | Fc-enhanced anti-wt1/hla antibody |
LT3736292T (lt) | 2013-12-17 | 2024-07-25 | Genentech, Inc. | Antikūnai prieš cd3 ir jų naudojimo būdai |
RU2020129339A (ru) | 2013-12-20 | 2020-10-02 | Дженентек, Инк. | Антитела с двойной специфичностью |
CN103738136B (zh) | 2014-01-27 | 2017-02-15 | 徐州重型机械有限公司 | 独立悬架***及具有该独立悬架***的起重机 |
US20160152725A1 (en) * | 2014-02-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
CN106573986A (zh) | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
HUE044814T2 (hu) | 2014-08-04 | 2019-11-28 | Hoffmann La Roche | Bispecifikus, T-sejt-aktiváló antigénkötõ molekulák |
CN107074970B (zh) | 2014-08-04 | 2021-07-30 | 弗雷德哈钦森癌症研究中心 | 特异性针对wt-1的t细胞免疫疗法 |
AR101844A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos y conjugados modificados genéticamente con cisteína |
CN107787332B (zh) | 2015-04-24 | 2022-09-09 | 豪夫迈·罗氏有限公司 | 多特异性抗原结合蛋白 |
WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
WO2017060201A1 (en) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anti-wt1/hla-specific antibodies |
CA3065402A1 (en) | 2017-05-31 | 2018-12-06 | Carsgen Therapeutics Co., Ltd. | Compositions and methods of cellular immunotherapy |
JP7394058B2 (ja) | 2017-12-21 | 2023-12-07 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ |
-
2018
- 2018-12-20 BR BR112020011469-3A patent/BR112020011469A2/pt unknown
- 2018-12-20 AR ARP180103765A patent/AR114001A1/es unknown
- 2018-12-20 TW TW107146108A patent/TWI805665B/zh active
- 2018-12-20 KR KR1020207020450A patent/KR102575787B1/ko active IP Right Grant
- 2018-12-20 WO PCT/EP2018/086055 patent/WO2019122052A2/en unknown
- 2018-12-20 JP JP2020533185A patent/JP6933778B2/ja active Active
- 2018-12-20 SG SG11202005632SA patent/SG11202005632SA/en unknown
- 2018-12-20 MX MX2020006119A patent/MX2020006119A/es unknown
- 2018-12-20 CN CN201880081252.8A patent/CN111527107A/zh active Pending
- 2018-12-20 AU AU2018390881A patent/AU2018390881A1/en active Pending
- 2018-12-20 PE PE2020000727A patent/PE20201149A1/es unknown
- 2018-12-20 US US16/228,102 patent/US11192957B2/en active Active
- 2018-12-20 EP EP18833866.9A patent/EP3728317A2/en active Pending
- 2018-12-20 MA MA051302A patent/MA51302A/fr unknown
- 2018-12-20 CA CA3084105A patent/CA3084105A1/en active Pending
-
2020
- 2020-05-29 CO CONC2020/0006600A patent/CO2020006600A2/es unknown
- 2020-06-17 CL CL2020001629A patent/CL2020001629A1/es unknown
- 2020-06-17 IL IL275471A patent/IL275471A/en unknown
- 2020-06-19 PH PH12020550952A patent/PH12020550952A1/en unknown
-
2021
- 2021-04-02 JP JP2021063539A patent/JP2021129561A/ja active Pending
- 2021-11-04 US US17/519,436 patent/US20220411534A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111527107A (zh) | 2020-08-11 |
AU2018390881A1 (en) | 2020-07-02 |
TW201930356A (zh) | 2019-08-01 |
IL275471A (en) | 2020-08-31 |
US20220411534A1 (en) | 2022-12-29 |
PE20201149A1 (es) | 2020-10-26 |
US20190248916A1 (en) | 2019-08-15 |
CL2020001629A1 (es) | 2020-11-27 |
CA3084105A1 (en) | 2019-06-27 |
JP2021507698A (ja) | 2021-02-25 |
WO2019122052A3 (en) | 2019-08-01 |
CO2020006600A2 (es) | 2020-06-19 |
MX2020006119A (es) | 2020-08-24 |
US11192957B2 (en) | 2021-12-07 |
BR112020011469A2 (pt) | 2020-11-24 |
SG11202005632SA (en) | 2020-07-29 |
JP2021129561A (ja) | 2021-09-09 |
KR102575787B1 (ko) | 2023-09-08 |
RU2020123129A (ru) | 2022-01-21 |
JP6933778B2 (ja) | 2021-09-08 |
EP3728317A2 (en) | 2020-10-28 |
WO2019122052A2 (en) | 2019-06-27 |
MA51302A (fr) | 2021-03-31 |
TWI805665B (zh) | 2023-06-21 |
PH12020550952A1 (en) | 2021-03-22 |
KR20200104331A (ko) | 2020-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020008940A2 (es) | Anticuerpos de unión a gprc5d | |
CL2021001506A1 (es) | Anticuerpos que se unen a cd3 | |
AR114001A1 (es) | Anticuerpos que se unen a hla- a2 / wt1 | |
CO2017013710A2 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t. | |
CO2017003048A2 (es) | Moléculas de unión a antígeno biespecíficas activadoras de células t que se unen a cd3 y al receptor 1 de folato (folr1) | |
CO2022000803A2 (es) | Anticuerpos que se fijan a gprc5d | |
AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CR20170032A (es) | Moleculas biespecíficas de unión a antígeno activadoras de células t | |
UY36859A (es) | Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas | |
AR094896A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CO2018005695A2 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
CR20180105A (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
CO2022009019A2 (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
AR087608A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
CO2019010164A2 (es) | Anticuerpos que se unen a steap-1 | |
CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
CO2020014515A2 (es) | Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
AR122658A1 (es) | Anticuerpos que se unen a cd3 | |
AR113343A1 (es) | ANTICUERPO MONOCLONAL ANTI-IL-5Ra | |
AR119972A2 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
AR105714A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos |